M. Omizo

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.

J. Krege, W. Utian, S. Broy, 2009, The Journal of clinical endocrinology and metabolism.

Genotype‐phenotype study in patients with valosin‐containing protein mutations associated with multisystem proteinopathy

Charles D. Smith, V. Kimonis, A. Wang, 2018, Clinical genetics.

Skeletal Consequences of Hormone Therapy Discontinuance: A Systematic Review

L. Wehren, J. Simon, S. Silfen, 2006, Obstetrical & gynecological survey.

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

G. Dalsky, D. Donley, J. S. San Martin, 2005, Archives of internal medicine.

Novel valosin-containing protein mutations associated with multisystem proteinopathy

H. Yoshioka, M. Grafe, A. Lakatos, 2018, Neuromuscular Disorders.

Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial

E. Schwartz, E. Glass, J. Krege, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.

H. Genant, T. Fuerst, K. Engelke, 2010, Bone.

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.

Jacques P. Brown, H. Genant, T. Fuerst, 2010, Bone.